clinical trial · NCT07081932
A Study in Healthy Men to Test How Bosentan Influences the Amount of Nerandomilast in the Blood
Boehringer Ingelheim·phase1·completed·n = 16
HealthyNerandomilastBosentan
brief summary
The main objective of this trial is to investigate the effect of bosentan, a moderate Cytochrome P450 (CYP) 3A inducer on the single dose pharmacokinetics of nerandomilast.
started
Aug 26, 2025
primary completion
Sep 27, 2025
completion
Oct 8, 2025
last updated
Oct 14, 2025
official title
The Effect of Multiple Oral Doses of Bosentan on the Single Oral Dose Pharmacokinetics of Nerandomilast in Healthy Male Subjects (an Open-label, Two-treatment, Two-period Fixed Sequence Trial)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol